Figure 1

Cumulative incidence of relapse in BCP-ALL and T-ALL patients according to the expression of hERG1A and hERG1B. Cumulative incidence of relapse was estimated by adjusting for competing risks (death) and compared using the Gray test. Statistical analyses were performed with R. (a) Cumulative incidence of relapse in BCP-ALL patients according to the expression of hERG1A. (b) Cumulative incidence of relapse in T-ALL patients according to the expression of hERG1A. (c) Cumulative incidence of relapse in T-ALL patients relative to the expression of hERG1B, according to different cutoffs (6.8 and 1.3) and multivariate analysis.